AeroRx Therapeutics
$31.4Mtotal raised · 2 rounds on record
$21Mlatest round · Series A · Oct 2025 · 13 mo ago
10+team · employees, estimated range
2024founded
Overview
Developing Best-in-Class Nebulized COPD Treatments for Patients Underserved by Inhalers. AeroRx is a clinical-stage biopharmaceutical company developing best-in-class combination treatments for high-risk COPD patients.
Funding and backers
Total raised
$31.4M
2 rounds on record
Latest round
$21M
Series A · Oct 2025 · 13 mo ago
Team
11-50
employees, estimated range
The money's age
Due for its next round
13 months since the last round · not hiring
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series A | Oct 2025 | $21M | — | aerorxtx.com |
| Venture round | Sep 2025 | $10.4M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | AeroRx Therapeutics, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Ahmet Tutuncu M.D. Ph.D.Executive Officer, DirectorSEC Form D
Tighe ReardonExecutive OfficerSEC Form D
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
EnteroBiotix is a clinical-stage biopharmaceutical company developing best-in-class full-spectrum microbial therapeutics.
EpiEndo Pharmaceuticals. We are a clinical-stage biopharmaceutical company committed to developing oral drugs for chronic respiratory…
About Us Aplagon is a clinical-stage biopharmaceutical company developing first-in-class therapeutics for a wide range of…
Response Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing treatments for weight management and metabolic…
Veradermics is a dermatologist-founded, late clinical-stage biopharmaceutical company.
Explore the future of inhaled therapy for COPD with AirNexis's innovative AN01 dry powder inhaler designed for ease of use.
People
Ahmet Tutuncu M.D. Ph.D.
Executive Officer, Director
Tighe Reardon
Executive Officer
Sanford Madigan Ph.D.
Director
John Patton Ph.D.
Director
Heather Preston M.D.
Director
Jay Lichter Ph.D.
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
News
AeroRx Therapeutics Presents Modeling-Based Population Pharmacokinetics and Efficacy Analyses Supporting Once-Daily Dosing of Inhaled AERO-007 for COPD at ERS Congress 2026
About Team Pipeline News Investors Contact About Team Pipeline News Investors Contact About Team Pipeline News Investors Contact Press Release AeroRx Therapeutics Presents Modeling-Based Population Pharmacokinetics and Efficacy Analyses Supporting Once-Da
Read more
Report
AeroRx Therapeutics Presents Positive Phase 2a Data for Inhaled AERO-007, the First Potential Nebulized LABA+LAMA Fixed-Dose Combination in Development for COPD
About Team Pipeline News Investors Contact About Team Pipeline News Investors Contact About Team Pipeline News Investors Contact Press Release AeroRx Therapeutics Presents Positive Phase 2a Data for Inhaled AERO-007, the First Potential Nebulized LABA+LAM
Read more
Report
AeroRx Therapeutics Announces $21 Million Series A Financing to Advance Inhaled AERO-007, the First Nebulized LABA/LAMA for COPD, into Late-Stage Clinical Development
AeroRx Therapeutics is developing potential best-in-class nebulized combination therapies to improve COPD treatment.
Read more
Report
COPD Trends Brief - Prevalence
View chronic bronchitis, emphysema, and COPD prevalence (number of cases) trends and disparities by age, gender, and race/ethnicity, overlapping diagnoses, underdiagnosis, and state.
Read more
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
La Jolla
United States
HQ
10-50 est. staff